Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program -- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in advance of World Duchenne Awareness Day on September 7, grants are designed to fund projects supporting the Duchene community on a global scale -- BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its third annual DREAMS Grant Prog...
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 54,360 restricted stock units (“RSUs”) and options to purchase 38,850 shares of the Company’s common stock to seven newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2025. The options have an exercise price of $5.47 per share, which is equal to the closing price of the Company's...
Shentel Brings Fiber-to-the-Home Internet to Radford, VA 100% Fiber-Optic Network with Speeds up to 5Gbps EDINBURG, Va., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN), a leading provider of broadband services, is currently upgrading its network in Radford, Virginia, with 100% fiber-to-the-home internet service. Shentel Fiber will bring symmetrical, multi-gig internet speeds to both residential and business customers, and construction is expected to be completed by the end of the year. “We are pleased with the investment Shentel is ma...
Shenandoah Telecommunications to Present at the Bank of America Media, Communications, & Entertainment Conference EDINBURG, Va., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) announced that Ed McKay, Chief Operating Officer and Jim Volk, Chief Financial Officer will present at the Bank of America 2025 Media, Communications, & Entertainment Conference at Bank of America Pavillion in New York, on September 3, 2025 at 9:40AM E.T. Investors may access a live webcast of the presentation at this or investor.shentel.com. The webcast will be avai...
Shenandoah Telecommunications Appoints Angela M. Olsen as General Counsel EDINBURG, Va., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel” or the “Company”) (Nasdaq: SHEN) announces that Angela M. Olsen has joined the Company as Vice President-Legal and General Counsel. Ms. Olsen will be a member of the senior executive team, reporting to the President and Chief Executive Officer. Ms. Olsen has over 25 years of legal experience in corporate, private practice and government legal settings, across a range of industries. Ms. Olsen previously served as Genera...
Shenandoah Telecommunications Wins Prestigious CableFax Top Ops Work Culture Award EDINBURG, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN) has been honored with the 2025 CableFax Top Ops Award for Work Culture. Each year, the Top Ops Awards recognize the outstanding achievements of leading cable operators across 15 categories. The Work Culture category celebrates organizations that work to improve the lives of their employees and foster an environment of connection among colleagues and with the company itself. “We are grateful to...
Entrada Therapeutics Reports Second Quarter 2025 Financial Results -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.